Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
5. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206—1218.
6. Lauer MS. Aspirin for primary prevention of coronary events. New Engl J Med 2002; 346: 1468—1474.
7. Wu KK. Aspirin and salicylate. An old remedy with a new twist. Circulation 2000; 102: 2022—2023.
8. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclo-oxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057—2072.
9. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793—798.
10. Redondo S, Santos-Gallego CG, Ganado P, et al. Acetylsalicilic acid inhibits cell proliferation by transforming growth factor-b. Circulation 2002; 107: 626.
11. Husian S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial disfunction in atherosclerosis. Circulation 1998; 97: 716—720.
12. Tiran A, Gruber HJ, Graier WS, et al. Aspirin inhibits Chlamydia pneumonia-induced nuclear factor-kB activation, cytokune expression. And bacterial development in human
endothelia; cells. Arterioscl Thromb Vasc Biol 2002; 22: 1075—1080.
13. Yoneda H, Miura K, Matsushima H, et al. Aspirin inhibits Chlamydia pneumonia-induced NF-kB activation, cyclooxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamidia growth. J. Med Microbiol 2002; 52: 409—415.
14. Steer K, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997; 77: 333— 337.
15. Oberle S, Polte T, Abate A, et al. Aspirin increases ferritin synthesis in endothelial cells. A novel antioxidant pathway. Circ Res 1998; 82: 1016—1020.
16. Xu X-M, Sansores-Garcia L, Chen X-M, et al. Supression of inducible cycloxygenase 2 gene trancription by aspirin and sodium salycylate. Proc Natl Acd Sci USA 1999; 96: 5292—5297.
17. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin. Circulation 2002; 105: 2600—2604.
18. Herrman M. Salicilic acid: an old dog, new tricks, and staphylococcal disease. J Clin Invest 2003; 112: 149—151.
19. Cyrus T, Sung S, Zhao L, et al. Effect of low-dose aspirinon vascular inflammation, plaque stability, and angiogeneasis in low-density lipoprotein receptor-deficiency mice. Circulation 2002; 10: 1282—1287.
20. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997; 336: 973—979.
21. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001; 345: 433—442.
22. Насонов ЕЛ. Специфические ингибиторы ЦОГ-2:решенные и нерешенные проблемы. Клин. фармакология и терапия, 2000; 1: 57— 64.
23. Насонов ЕЛ. Анальгетическая терапия в ревматологии. Путешествие между Сциллой и Харибдой. Клин. Фарм. Терапия, 2003; 12 (3): 64—69.
24. Baigent C, Patrono C. Selective cyclooxyge-nase 2 inhibitors, aspirin, and cardiovascular dis-
SHS-OOO4.qxd 21.11.2006 16:56 Page 42*4
24
Насонов Е.Л. Антифосфолипидный синдром.
ease. A reappraisal. Arthritis Rheum 2003; 48: 12—20.
25. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2. PNAS 1999; 96: 272—277.
26. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539—541.
27. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular response and thrombosis in canine arteries. Circulation 2001; 104: 820—825.
28. Shinmura K, Tang XL, Wang Y et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase ischemic preconditioning in conscious rabbits. Proc Nat Acad Sci USA 2000; 97: 10197—10202.
29. MarcusAJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation. N Engl J Med 2002; 347: 1025—1026.
30. Bombardier C, Lane L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecox-ib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000; 343:1520—1528.
31. Crofford LJ, Oates JC, McCune WI, et al. Thrombosis in patients with connective tissue disease treated with specific cycloxygenase-2 inhibitors: a report of four cases. Arthritis Rheum 2000; 3: 1891—1896.
32. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954—959
33. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425—430.
34. Konstam MA, Weir AR. Current persective on the cardiovascular effects of coxibs. Clev Clin J Med 2002; (Suppl 1):SI-47-SI-52.
35. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum (Arthritis Care&Res) 2002; 47:349—355.
